FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020329335> ?p ?o ?g. }

• W3020329335 endingPage "2019" @default.
• W3020329335 startingPage "00187" @default.
• W3020329335 abstract "Inhaled corticosteroid/long-acting β 2 -agonist combination therapy is a recommended treatment option for patients with chronic obstructive pulmonary disease (COPD) and increased exacerbation risk, particularly those with elevated blood eosinophil levels. SOPHOS ( NCT02727660 ) evaluated the efficacy and safety of two doses of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) versus formoterol fumarate dihydrate (FF) MDI, each delivered using co-suspension delivery technology, in patients with moderate-to-very severe COPD and a history of exacerbations. In this phase 3, randomised, double-blind, parallel-group, 12–52-week, variable length study, patients received twice-daily BFF MDI 320/10 µg or 160/10 µg, or FF MDI 10 µg. The primary endpoint was change from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV 1 ) at week 12. Secondary and other endpoints included assessments of moderate/severe COPD exacerbations and safety. The primary analysis (modified intent-to-treat) population included 1843 patients (BFF MDI 320/10 µg, n=619; BFF MDI 160/10 µg, n=617; and FF MDI, n=607). BFF MDI 320/10 µg and 160/10 µg improved morning pre-dose trough FEV 1 at week 12 versus FF MDI (least squares mean differences 34 mL [p=0.0081] and 32 mL [p=0.0134], respectively), increased time to first exacerbation (hazard ratios 0.827 [p=0.0441] and 0.803 [p=0.0198], respectively) and reduced exacerbation rate (rate ratios 0.67 [p=0.0001] and 0.71 [p=0.0010], respectively). Lung function and exacerbation benefits were driven by patients with blood eosinophil counts ≥150 cells·mm −3 . The incidence of adverse events was similar, and pneumonia rates were low (≤2.4%) across treatments. SOPHOS demonstrated the efficacy and tolerability of BFF MDI 320/10 µg and 160/10 µg in patients with moderate-to-very severe COPD at increased risk of exacerbations." @default.
• W3020329335 created "2020-05-01" @default.
• W3020329335 creator A5004903602 @default.
• W3020329335 creator A5007232285 @default.
• W3020329335 creator A5016161340 @default.
• W3020329335 creator A5020504157 @default.
• W3020329335 creator A5021493691 @default.
• W3020329335 creator A5022001894 @default.
• W3020329335 creator A5039740362 @default.
• W3020329335 creator A5052712328 @default.
• W3020329335 creator A5082568705 @default.
• W3020329335 date "2020-04-01" @default.
• W3020329335 modified "2023-09-27" @default.
• W3020329335 title "Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD" @default.
• W3020329335 cites W1520204119 @default.
• W3020329335 cites W1987881697 @default.
• W3020329335 cites W2001104945 @default.
• W3020329335 cites W2035374789 @default.
• W3020329335 cites W2057984874 @default.
• W3020329335 cites W2058580481 @default.
• W3020329335 cites W2077672954 @default.
• W3020329335 cites W2107272163 @default.
• W3020329335 cites W2108678383 @default.
• W3020329335 cites W2120629366 @default.
• W3020329335 cites W2133986277 @default.
• W3020329335 cites W2142724633 @default.
• W3020329335 cites W2145152803 @default.
• W3020329335 cites W2146831425 @default.
• W3020329335 cites W2166432084 @default.
• W3020329335 cites W2170298115 @default.
• W3020329335 cites W2317895461 @default.
• W3020329335 cites W2324038222 @default.
• W3020329335 cites W2604414288 @default.
• W3020329335 cites W2715795126 @default.
• W3020329335 cites W2751243049 @default.
• W3020329335 cites W2761239349 @default.
• W3020329335 cites W2766594601 @default.
• W3020329335 cites W2783705291 @default.
• W3020329335 cites W2889531427 @default.
• W3020329335 cites W2890960652 @default.
• W3020329335 cites W2891482814 @default.
• W3020329335 cites W2904259512 @default.
• W3020329335 cites W2960506719 @default.
• W3020329335 cites W2969213710 @default.
• W3020329335 doi "https://doi.org/10.1183/23120541.00187-2019" @default.
• W3020329335 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7184113" @default.
• W3020329335 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32363206" @default.
• W3020329335 hasPublicationYear "2020" @default.
• W3020329335 type Work @default.
• W3020329335 sameAs 3020329335 @default.
• W3020329335 citedByCount "6" @default.
• W3020329335 countsByYear W30203293352021 @default.
• W3020329335 countsByYear W30203293352022 @default.
• W3020329335 countsByYear W30203293352023 @default.
• W3020329335 crossrefType "journal-article" @default.
• W3020329335 hasAuthorship W3020329335A5004903602 @default.
• W3020329335 hasAuthorship W3020329335A5007232285 @default.
• W3020329335 hasAuthorship W3020329335A5016161340 @default.
• W3020329335 hasAuthorship W3020329335A5020504157 @default.
• W3020329335 hasAuthorship W3020329335A5021493691 @default.
• W3020329335 hasAuthorship W3020329335A5022001894 @default.
• W3020329335 hasAuthorship W3020329335A5039740362 @default.
• W3020329335 hasAuthorship W3020329335A5052712328 @default.
• W3020329335 hasAuthorship W3020329335A5082568705 @default.
• W3020329335 hasBestOaLocation W30203293351 @default.
• W3020329335 hasConcept C126322002 @default.
• W3020329335 hasConcept C168563851 @default.
• W3020329335 hasConcept C203092338 @default.
• W3020329335 hasConcept C2776042228 @default.
• W3020329335 hasConcept C2776136866 @default.
• W3020329335 hasConcept C2776780178 @default.
• W3020329335 hasConcept C2776804153 @default.
• W3020329335 hasConcept C2777014857 @default.
• W3020329335 hasConcept C2779871671 @default.
• W3020329335 hasConcept C2780261241 @default.
• W3020329335 hasConcept C2780667556 @default.
• W3020329335 hasConcept C2909086917 @default.
• W3020329335 hasConcept C42219234 @default.
• W3020329335 hasConcept C71924100 @default.
• W3020329335 hasConceptScore W3020329335C126322002 @default.
• W3020329335 hasConceptScore W3020329335C168563851 @default.
• W3020329335 hasConceptScore W3020329335C203092338 @default.
• W3020329335 hasConceptScore W3020329335C2776042228 @default.
• W3020329335 hasConceptScore W3020329335C2776136866 @default.
• W3020329335 hasConceptScore W3020329335C2776780178 @default.
• W3020329335 hasConceptScore W3020329335C2776804153 @default.
• W3020329335 hasConceptScore W3020329335C2777014857 @default.
• W3020329335 hasConceptScore W3020329335C2779871671 @default.
• W3020329335 hasConceptScore W3020329335C2780261241 @default.
• W3020329335 hasConceptScore W3020329335C2780667556 @default.
• W3020329335 hasConceptScore W3020329335C2909086917 @default.
• W3020329335 hasConceptScore W3020329335C42219234 @default.
• W3020329335 hasConceptScore W3020329335C71924100 @default.
• W3020329335 hasFunder F4320307770 @default.
• W3020329335 hasIssue "2" @default.
• W3020329335 hasLocation W30203293351 @default.
• W3020329335 hasLocation W30203293352 @default.
• W3020329335 hasLocation W30203293353 @default.

• next